Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Biocytogen and Sihuan partner to advance new therapeutics for weight loss
  • M&A / Deals

Biocytogen and Sihuan partner to advance new therapeutics for weight loss

Pharmaceutical Business Review

Under the agreement, Biocytogen's fully human antibody discovery platform will be combined with Sihuan Pharmaceutical's capabilities in drug development, manufacturing, and commercialisation.

M&A / DealsMetabolic & GLP-1Read full story

pharminent April 2, 2026 (Last updated: April 2, 2026)

Pharmaceutical Business Review

Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation.

M&A / DealsMetabolic & GLP-1Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Threat of Trump’s pharma tariffs looms again
Next: Merck KGaA acquires JSR chromatography business

Related Stories

  • M&A / Deals

J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout

pharminent July 31, 2026
  • M&A / Deals

Eisai and CORE Biomedicine agree on global licence for oncology pipeline

pharminent July 29, 2026
  • M&A / Deals

Argenx signs agreement to buy Forte Biosciences for $2.2bn

pharminent July 28, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.